Białko aktywujące 5-lipooksygenazę (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Białko aktywujące 5-lipooksygenazę" in Polish language version.

refsWebsite

Global rank Polish rank

6nih.gov

4^th place

7^th place

5doi.org

2^nd place

6^th place

doi.org

Yandava CN, Kennedy BP, Pillari A, Duncan AM, Drazen JM. Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12. „Genomics”. 56 (1), s. 131–3, February 1999. DOI: 10.1006/geno.1998.5651. PMID: 10036194. (ang.).
Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. „Prostaglandins Leukot Essent Fatty Acids”. 69 (2-3), s. 99–109, 2003. DOI: 10.1016/S0952-3278(03)00070-X. PMID: 12895592. (ang.).
Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. „Science”. 317 (5837), s. 510–2, July 2007. DOI: 10.1126/science.1144346. PMID: 17600184. (ang.).
Manev H, Manev R. 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. „Med Hypotheses”. 66 (3), s. 501–3, 2006. DOI: 10.1016/j.mehy.2005.09.031. PMID: 16278051. (ang.).

dx.doi.org

A.A. Musiyenko A.A. i inni, A Novel 5-Lipoxygenase-Activating Protein Inhibitor, AM679, Reduces Inflammation in the Respiratory Syncytial Virus-Infected Mouse Eye, G.G. Bain, J.F.J.F. Evans, S.S. Barik, „Clinical and Vaccine Immunology”, 11, 16, 2009, s. 1654, DOI: 10.1128/CVI.00220-09, PMID: 19759251 (ang.).

nih.gov

ncbi.nlm.nih.gov

Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA. Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). „J. Biol. Chem.”. 266 (13), s. 8511–6, 05-1991. PMID: 1673682. (ang.).
Yandava CN, Kennedy BP, Pillari A, Duncan AM, Drazen JM. Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12. „Genomics”. 56 (1), s. 131–3, February 1999. DOI: 10.1006/geno.1998.5651. PMID: 10036194. (ang.).
Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. „Prostaglandins Leukot Essent Fatty Acids”. 69 (2-3), s. 99–109, 2003. DOI: 10.1016/S0952-3278(03)00070-X. PMID: 12895592. (ang.).
Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. „Science”. 317 (5837), s. 510–2, July 2007. DOI: 10.1126/science.1144346. PMID: 17600184. (ang.).
Manev H, Manev R. 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. „Med Hypotheses”. 66 (3), s. 501–3, 2006. DOI: 10.1016/j.mehy.2005.09.031. PMID: 16278051. (ang.).
A.A. Musiyenko A.A. i inni, A Novel 5-Lipoxygenase-Activating Protein Inhibitor, AM679, Reduces Inflammation in the Respiratory Syncytial Virus-Infected Mouse Eye, G.G. Bain, J.F.J.F. Evans, S.S. Barik, „Clinical and Vaccine Immunology”, 11, 16, 2009, s. 1654, DOI: 10.1128/CVI.00220-09, PMID: 19759251 (ang.).